A Review of the First Anti-Evaporative Prescription Treatment for Dry Eye Disease: Perfluorohexyloctane Ophthalmic Solution

doi:10.37765/ajmc.2023.89464

Cited by 2 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of the current treatments for ocular surface diseases are eye drop formulations, including Miebo, Restasis, a cyclosporin drug, and Eysuvis, an ophthalmic suspension with loteprednol etabonate, all of which are FDA-approved treatments for dry eye disease [173][174][175][176]. Approved eye drops for use in glaucoma include prostaglandins such as latanoprost, travoprost, tafluprost, and bimatoprost, as well as Rho kinase inhibitors such as Netarsudil [177,178].…”

Section: Eye Dropsmentioning

confidence: 99%

Seeing the Future: A Review of Ocular Therapy

Whalen,

Akula,

McNamee

et al. 2024

Bioengineering

View full text Add to dashboard Cite

Ocular diseases present a unique challenge and opportunity for therapeutic development. The eye has distinct advantages as a therapy target given its accessibility, compartmentalization, immune privilege, and size. Various methodologies for therapeutic delivery in ocular diseases are under investigation that impact long-term efficacy, toxicity, invasiveness, and delivery range. While gene, cell, and antibody therapy and nanoparticle delivery directly treat regions that have been damaged by disease, they can be limited in the duration of the therapeutic delivery and have a focal effect. In contrast, contact lenses and ocular implants can more effectively achieve sustained and widespread delivery of therapies; however, they can increase dilution of therapeutics, which may result in reduced effectiveness. Current therapies either offer a sustained release or a broad therapeutic effect, and future directions should aim toward achieving both. This review discusses current ocular therapy delivery systems and their applications, mechanisms for delivering therapeutic products to ocular tissues, advantages and challenges associated with each delivery system, current approved therapies, and clinical trials. Future directions for the improvement in existing ocular therapies include combination therapies, such as combined cell and gene therapies, as well as AI-driven devices, such as cortical implants that directly transmit visual information to the cortex.

show abstract

Section: Eye Dropsmentioning

confidence: 99%

Seeing the Future: A Review of Ocular Therapy

Whalen,

Akula,

McNamee

et al. 2024

Bioengineering

View full text Add to dashboard Cite

show abstract

Highlights on Fluorine-containing Drugs Approved by U.S. FDA in 2023

Ali,

Bolinger,

Zhou

2024

CTMC

View full text Add to dashboard Cite

Fluorine continues to show its potential applications in drug discovery and development, as reflected by twelve drugs being fluorinated out of the fifty-five approved by the FDA in 2023. This concise review highlights the discovery of each of these fluorine-containing drugs in the past year, including its brand name, date of approval, composition, sponsors, indication, and mechanism of action. The relevant future trend is also briefly discussed.

show abstract

A Review of the First Anti-Evaporative Prescription Treatment for Dry Eye Disease: Perfluorohexyloctane Ophthalmic Solution

Cited by 2 publications

References 28 publications

Seeing the Future: A Review of Ocular Therapy

Seeing the Future: A Review of Ocular Therapy

Highlights on Fluorine-containing Drugs Approved by U.S. FDA in 2023

Contact Info

Product

Resources

About